Hulin-Curtis S, Geary JK, MacLachlan BJ, Altmann DM, Baillon L, Cole DK, Greenshields-Watson A, Hesketh SJ, Humphreys IR, Jones IM, Lauder SN, Mason GH, Smart K, Scourfield DO, Scott J, Sukhova K, Stanton RJ, Wall A, Rizkallah PJ, Barclay WS, Gallimore A, Godkin A. A targeted single mutation in influenza A virus universal epitope transforms immunogenicity and protective immunity via CD4+ T cell activation. Cell Rep. 2024 May 30;43(6):114259

Chen Y, Mason GH, Scourfield DO, Greenshields-Watson A, Haigh TA, Sewell AK, Long HM, Gallimore AM, Rizkallah P, MacLachlan BJ, Godkin A. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+ T cell immunity. Cell Rep. 2023 Jul 18;42(8):112827. doi: 10.1016/j.celrep.2023.112827. Epub ahead of print. PMID: 37471227.

Milutinovic S, Gallimore A. The link between T cell activation and development of functionally useful tumour-associated high endothelial venules. Discov Immunol. 2023 Apr 24;2(1):kyad006. doi: 10.1093/discim/kyad006. PMID: 37287625; PMCID: PMC10243744.

Milutinovic S, Abe J, Jones E, Kelch I, Smart K, Lauder SN, Somerville M, Ware C, Godkin A, Stein JV, Bogle G, Gallimore A. Three-dimensional Imaging Reveals Immune-driven Tumor-associated High Endothelial Venules as a Key Correlate of Tumor Rejection Following Depletion of Regulatory T Cells. Cancer Res Commun. 2022 Dec 15;2(12):1641-1656. doi: 10.1158/2767-9764.CRC-21-0123. PMID: 36704666; PMCID: PMC7614106.

Scurr MJ, Lippiatt G, Capitani L, Bentley K, Lauder SN, Smart K, Somerville MS, Rees T, Stanton RJ, Gallimore A, Hindley JP, Godkin A. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nat Commun. 2022 Sep 21;13(1):5422. doi: 10.1038/s41467-022-32985-8. PMID: 36130936; PMCID: PMC9492763.

Lauder SN, Smart K, Bart VMT, Pires A, Scott J, Milutinovic S, Godkin A, Vanhaesebroeck B, Gallimore A. Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion. Br J Cancer. 2022 Nov;127(9):1595-1602. doi: 10.1038/s41416-022-01917-0. Epub 2022 Aug 19. PMID: 35986086; PMCID: PMC9596434.

Pires A, Burnell S, Gallimore A. Exploiting ECM remodelling to promote immune-mediated tumour destruction. Curr Opin Immunol. 2022 Feb;74:32-38. doi: 10.1016/j.coi.2021.09.006. Epub 2021 Oct 7. PMID: 34627015.

Scott J, Rees L, Gallimore A, Lauder SN. PI3K Isoform Immunotherapy for Solid Tumours. Curr Top Microbiol Immunol. 2022;436:369-392. doi: 10.1007/978-3-031-06566-8_16. PMID: 36243853.

Scurr MJ, Zelek WM, Lippiatt G, Somerville M, Burnell SEA, Capitani L, Davies K, Lawton H, Tozer T, Rees T, Roberts K, Evans M, Jackson A, Young C, Fairclough L, Tighe P, Wills M, Westwell AD, Morgan BP, Gallimore A, Godkin A. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers. Immunology. 2022 Feb;165(2):250-259. doi: 10.1111/imm.13433. Epub 2021 Dec 6. PMID: 34775604; PMCID: PMC8653009.

MacLachlan BJ, Mason GH, Greenshields-Watson A, Triebel F, Gallimore A, Cole DK, Godkin A. Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. Eur J Immunol. 2021 Feb;51(2):331-341. doi: 10.1002/eji.202048753. Epub 2020 Oct 9. PMID: 32920841; PMCID: PMC8101287.

Thomson A, Bento DFC, Scurr MJ, Smart K, Somerville MS, Keita ÅV, Gallimore A, Godkin A. Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. Br J Cancer. 2021 Apr;124(9):1552-1555. doi: 10.1038/s41416-021-01283-3. Epub 2021 Mar 5. PMID: 33674735; PMCID: PMC8076199.

Teijeira Crespo A, Burnell S, Capitani L, Bayliss R, Moses E, Mason GH, Davies JA, Godkin AJ, Gallimore AM, Parker AL. Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity. Immunology. 2021 Aug;163(4):389-398. doi: 10.1111/imm.13323. Epub 2021 Mar 28. PMID: 33638871; PMCID: PMC8274202.

Burnell SEA, Capitani L, MacLachlan BJ, Mason GH, Gallimore AM, Godkin A. Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunother Adv. 2021 Dec 20;2(1):ltab025. doi: 10.1093/immadv/ltab025. PMID: 35265944; PMCID: PMC8895726.

Lauder SN, Vanhaesebroeck B, Gallimore A. Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach. Br J Cancer. 2021 Aug;125(4):467-469. doi: 10.1038/s41416-021-01285-1. Epub 2021 Apr 6. PMID: 33824480; PMCID: PMC8368216.

Milutinovic S, Abe J, Godkin A, Stein JV, Gallimore A. The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity. Trends Cancer. 2021 Mar;7(3):214-225. doi: 10.1016/j.trecan.2020.10.001. Epub 2020 Oct 31. PMID: 33132107; PMCID: PMC9213382.

Lauder SN, Smart K, Kersemans V, Allen D, Scott J, Pires A, Milutinovic S, Somerville M, Smart S, Kinchesh P, Lopez-Guadamillas E, Hughes E, Jones E, Scurr M, Godkin A, Friedman LS, Vanhaesebroeck B, Gallimore A. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. J Immunother Cancer. 2020 Oct;8(2):e000693. doi: 10.1136/jitc-2020-000693. PMID: 33093155; PMCID: PMC7583804.

Hughes E, Lauder SN, Smart K, Bloom A, Scott J, Jones E, Somerville M, Browne M, Blainey A, Godkin A, Ager A, Gallimore A. Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunol Immunother. 2020 Oct;69(10):2063-2073. doi: 10.1007/s00262-020-02603-x. Epub 2020 May 23. PMID: 32447412; PMCID: PMC7511476.

Scurr MJ, Greenshields-Watson A, Campbell E, Somerville MS, Chen Y, Hulin-Curtis SL, Burnell SEA, Davies JA, Davies MM, Hargest R, Phillips S, Christian AD, Ashelford KE, Andrews R, Parker AL, Stanton RJ, Gallimore A, Godkin A. Cancer Antigen Discovery Is Enabled by RNA Sequencing of Highly Purified Malignant and Nonmalignant Cells. Clin Cancer Res. 2020 Jul 1;26(13):3360-3370. doi: 10.1158/1078-0432.CCR-19-3087. Epub 2020 Mar 2. PMID: 32122920.

Pires A, Greenshields-Watson A, Jones E, Smart K, Lauder SN, Somerville M, Milutinovic S, Kendrick H, Hindley JP, French R, Smalley MJ, Watkins WJ, Andrews R, Godkin A, Gallimore A. Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection. Cancer Immunol Res. 2020 Dec;8(12):1520-1531. doi: 10.1158/2326-6066.CIR-20-0070. Epub 2020 Oct 6. PMID: 33023965; PMCID: PMC7611107.

Greenshields-Watson A, Attaf M, MacLachlan BJ, Whalley T, Rius C, Wall A, Lloyd A, Hughes H, Strange KE, Mason GH, Schauenburg AJ, Hulin-Curtis SL, Geary J, Chen Y, Lauder SN, Smart K, Vijaykrishna D, Grau ML, Shugay M, Andrews R, Dolton G, Rizkallah PJ, Gallimore AM, Sewell AK, Godkin AJ, Cole DK. CD4+ T Cells Recognize Conserved Influenza A Epitopes through Shared Patterns of V-Gene Usage and Complementary Biochemical Features. Cell Rep. 2020 Jul 14;32(2):107885. doi: 10.1016/j.celrep.2020.107885. PMID: 32668259; PMCID: PMC7370177.

Thomson A, Smart K, Somerville MS, Lauder SN, Appanna G, Horwood J, Sunder Raj L, Srivastava B, Durai D, Scurr MJ, Keita ÅV, Gallimore AM, Godkin A. The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterol. 2019 Jun 20;19(1):98. doi: 10.1186/s12876-019-1002-4. PMID: 31221083; PMCID: PMC6585111.

MacLachlan BJ, Dolton G, Papakyriakou A, Greenshields-Watson A, Mason GH, Schauenburg A, Besneux M, Szomolay B, Elliott T, Sewell AK, Gallimore A, Rizkallah P, Cole DK, Godkin A. Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. J Biol Chem. 2019 Dec 27;294(52):20246-20258. doi: 10.1074/jbc.RA119.009437. Epub 2019 Oct 16. PMID: 31619516; PMCID: PMC6937582.

Besneux M, Greenshields-Watson A, Scurr MJ, MacLachlan BJ, Christian A, Davies MM, Hargest R, Phillips S, Godkin A, Gallimore A. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunol Immunother. 2019 Feb;68(2):247-256. doi: 10.1007/s00262-018-2266-1. Epub 2018 Nov 7. PMID: 30406375; PMCID: PMC6394487.

Gallimore A, Quezada SA, Roychoudhuri R. Regulatory T cells in cancer: where are we now? Immunology. 2019 Jul;157(3):187-189. doi: 10.1111/imm.13088. PMID: 31225653; PMCID: PMC6587319.

Besneux M, Greenshields-Watson A, Scurr MJ, MacLachlan BJ, Christian A, Davies MM, Hargest R, Phillips S, Godkin A, Gallimore A. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunol Immunother. 2019 Feb;68(2):247-256. doi: 10.1007/s00262-018-2266-1. Epub 2018 Nov 7. PMID: 30406375; PMCID: PMC6394487.

Jones E, Gallimore A, Ager A. Defining High Endothelial Venules and Tertiary Lymphoid Structures in Cancer. Methods Mol Biol. 2018;1845:99-118. doi: 10.1007/978-1-4939-8709-2_7. PMID: 30141010.

Hughes E, Scurr M, Campbell E, Jones E, Godkin A, Gallimore A. T-cell modulation by cyclophosphamide for tumour therapy. Immunology. 2018 May;154(1):62-68. doi: 10.1111/imm.12913. Epub 2018 Mar 9. PMID: 29460448; PMCID: PMC5904691.

Colbeck EJ, Ager A, Gallimore A, Jones GW. Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease? Front Immunol. 2017 Dec 19;8:1830. doi: 10.3389/fimmu.2017.01830. PMID: 29312327; PMCID: PMC5742143.

Scurr M, Pembroke T, Bloom A, Roberts D, Thomson A, Smart K, Bridgeman H, Adams R, Brewster A, Jones R, Gwynne S, Blount D, Harrop R, Wright M, Hills R, Gallimore A, Godkin A. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017 Oct 12;3(10):e172579. doi: 10.1001/jamaoncol.2017.2579. Epub 2017 Oct 12. PMID: 28880972; PMCID: PMC5824319.

Colbeck EJ, Jones E, Hindley JP, Smart K, Schulz R, Browne M, Cutting S, Williams A, Parry L, Godkin A, Ware CF, Ager A, Gallimore A. Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor Destruction. Cancer Immunol Res. 2017 Nov;5(11):1005-1015. doi: 10.1158/2326-6066.CIR-17-0131. Epub 2017 Sep 25. PMID: 28947544; PMCID: PMC5668144.

Scurr M, Pembroke T, Bloom A, Roberts D, Thomson A, Smart K, Bridgeman H, Adams R, Brewster A, Jones R, Gwynne S, Blount D, Harrop R, Hills R, Gallimore A, Godkin A. Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Nov 15;23(22):6771-6780. doi: 10.1158/1078-0432.CCR-17-0895. Epub 2017 Aug 29. PMID: 28855352; PMCID: PMC5769815.